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Abstract: Alterations in muscle structure and function in chronic kidney disease (CKD) patients
are associated with poor outcomes. As key organelles in muscle cell homeostasis, mitochondrial
metabolism has been studied in the context of muscle dysfunction in CKD. We conducted a study
to determine the contribution of oxidative metabolism, glycolysis and fatty acid oxidation to the
muscle metabolism in CKD. Mice developed CKD by exposure to adenine in the diet. Muscle of
CKD mice showed significant weight loss compared to non-CKD mice, but only extensor digitorum
longus (EDL) muscle showed a decreased number of fibers. There was no difference in the proportion
of the various muscle fibers in CKD and non-CKD mice. Muscle of CKD mice had decreased
expression of proteins associated with oxidative phosphorylation but increased expression of enzymes
and transporters associated with glycolysis. In cell culture, myotubes exposed to uremic serum
demonstrated decreased oxygen consumption rates (OCR) when glucose was used as substrate,
conserved OCR when fatty acids were used and increased lactate production. In conclusion, mice
with adenine-induced CKD developed sarcopenia and with increased glycolytic metabolism but
without gross changes in fiber structure. In vitro models of uremic myopathy suggest fatty acid
utilization is preserved compared to decreased glucose utilization.
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1. Introduction
Uremic myopathy is the term used to refer to changes in muscle structure and function
that are present in patients with advanced kidney disease, including sarcopenia, cachexia,
protein energy wasting and muscle atrophy [1,2]. The clinical presentation of uremic
myopathy includes cardiomyopathy, muscle wasting, weakness, low endurance and fatigue [3,4]. Muscle wasting can lead to insulin resistance, accelerated cardiovascular disease,
longer hospital stays and increased mortality in patients with kidney disease [5–7].
Muscle loss or atrophy is a process widely observed with advanced age, but it is
also prevalent in patients with chronic diseases including cancer, heart failure and chronic
kidney disease (CKD) [4,7]. Muscle loss is more prevalent in patients with CKD than the
non-CKD population and prevalence increases as kidney disease progresses to end-stage
renal disease (ESRD) [8]. Muscle loss and decreased muscle function in patients with CKD
also contributes to the clinical syndrome of frailty. Around 7% of the elderly population
over 65 meet the definition of frailty while frailty affects up to 70% of ESRD patients over
age 65 years old and affects 47% of younger adults (18–64 years old) on dialysis [9–12].
Multiple mechanisms may contribute to uremic myopathy in kidney disease patients [13,14], including inflammation, exposure to elevated levels of reactive oxygen
species (ROS) [15], malnutrition and metabolic acidosis [16,17]. Mitochondria play a central
role in muscle cell metabolism, energy supply, regulation of energy-sensitive signaling
pathways, reactive oxygen species (ROS) production, calcium homeostasis and the regulation of apoptosis [18]. As key organelles in muscle cell homeostasis, mitochondrial
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metabolism has been studied in different disease processes including aging, muscular
dystrophies and even insulin resistance. Muscle of patients with kidney disease has lower
mitochondrial content and altered morphology with increased fragmentation, and swollen
cristae [19,20]. Additionally, mitochondrial dynamics are altered in CKD with increased
fission [20]. The process of mitochondrial renovation or mitochondrial biogenesis is also
a central component of skeletal muscle function and structure. CKD patients not only
have decreased mitochondrial content, with a lower mitochondrial DNA (mtDNA) copy
number, but decreased mitochondrial biogenesis and impaired overall function [19,21].
Impaired mitochondrial metabolism, despite preserved oxygen supply [22–26], is a key
process leading to uremic sarcopenia, although the mechanisms that lead to mitochondrial
dysfunction in CKD remain elusive.
The aim of the study is to determine the contribution of oxidative metabolism, glycolysis and fatty acid oxidation to the muscle metabolism in chronic kidney disease using
in vivo and in vitro models of advanced kidney disease.
2. Results
2.1. Characterization of Mouse Kidney Disease Model by Using Adenine Supplementation in Diet
To study the contribution of mitochondrial metabolism to muscle dysfunction in
kidney disease, we used a murine model of kidney disease by supplementing adenine
in the diet. Kidney disease was demonstrated by a significant increase in blood urea
nitrogen (BUN) in the CKD groups (Figure 1A). Mice fed an adenine diet also showed
other characteristics of advanced kidney disease, including anemia (Figure 1B) and marked
weight loss (Figure 1C). Adenine exposure induced changes in kidney histology including
interstitial fibrosis measured by collagen 3 accumulation in renal cortex and Trichrome
stain (Figure 1D, Supplementary Figure S1) as well as presence of tubular atrophy and
2,8-dihydroxyadenine crystals. Mice exposed to an adenine diet showed decreased exercise
endurance in a forced endurance treadmill test (Figure 1E,F). Mice exposed to adenine ran
shorter distances and reached exhaustion earlier than mice exposed to a normal diet. The
treadmill protocol gradually increased the speed over time to a maximum of 26 m/min,
when oxygen consumption in C57BL/6 mice reaches approximately 80% of VO2 max, which
is considered high-intensity exercise [27]. At high intensity, most of the energy utilized
by muscle comes from glycolytic metabolism and results in lactate release from muscle
fibers and accumulation in plasma [26]. Consequently, mice exposed to adenine showed an
increase in blood lactate levels post-exercise that was significantly higher than the lactate
levels observed after exercise in control mice (Figure 1G). The higher post-exercise lactate
in mice exposed to adenine suggest a prominent glycolytic response in uremic muscle. To
determine if the functional muscle changes are coupled with muscle structural changes,
we weighted the Soleus, extensor digitorum longus (EDL) and gastrocnemius muscles of
mice exposed to adenine and compared to muscle from mice on a control diet. Adenine
exposed mice showed lower muscle weights than control mice in the three muscle groups
(Figure 1H). In sum, mice exposed to an adenine-based diet developed CKD with high
BUN levels, anemia, weight loss and decreased exercise endurance. Furthermore, mice
with CKD had higher lactate levels post-exercise than control mice with loss of muscle
mass, reflecting a prominent glycolytic metabolism.
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Figure 2. Extensor digitorum longus (EDL) muscle fibers characteristics in mice with kidney disease.
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Figure 4. OXPHOS profile of gastrocnemius muscle from CKD mice compared to controls. (A) OXPHOS
profile and cytochrome C were evaluated by Western blot analysis on gastrocnemius muscle of mice
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Figure 4. OXPHOS profile of gastrocnemius muscle from CKD mice compared to controls. (A)
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Figure 5. Cells exposed to uremic serum have prominent glycolytic metabolism with decreased
OXPHOS. (A) Representative time course data of oxygen consumption rates (OCR) measurements in
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C2C12 differentiated myotubes treated with 5% control and uremic serum for 24 h. (B) OCRaggregated data. (C) Lactate production in differentiated myotubes exposed to 5% normal and
uremic serum after 24 h of serum treatment. (D) Lactate production in differentiated myotubes
exposed to normal and uremic serum for 24 h. After 24 h, the serum is washed out and lactate
production is measured 24 h and 48 h later in control media. (E) Extracellular H2 O2 production in
cells treated with uremic and control serum. (F) Representative time course data for OCR from fatty
acid oxidation (FAO) in myotubes treated with 5% normal or uremic serum. (G) FAO aggregated data.
Data from OCR experiments represent the mean of six technical replicates from two representative
experiments. Data from lactate experiment represent the mean of four technical replicates from two
representative experiments. Unpaired t test with Welch’s correction, error bars represent SEM. * p ≤
0.05, ** p < 0.01, *** p < 0.001. OCR, oxygen consumption rates. PFBSF, pentafluorobenzenesulfonyl
fluorescein. PL, proton leak. ATP, ATP production. MR, maximal respiration. SC, spare respiratory
capacity. NS, normal serum. US, uremic serum.

3. Discussion
Our study demonstrates that mice with advanced kidney disease have altered muscle
structure and function consistent with the phenotype of uremic myopathy. Mice with CKD
suffer significant muscle loss, decreased assembly of electron transport chain proteins as
well as enhanced glycolytic metabolism. Despite muscle loss, glycolytic and oxidative
muscle groups maintain the proportions of the different fiber types in our in vivo model of
adenine-induced nephropathy. In vitro models of advanced kidney disease, muscle cells
reveal that exposure to uremic serum impairs oxygen-derived OXPHOS but preserves FAO.
Loss of muscle mass with CKD has been previously documented in patients as well as
in animal models [25,30]. Muscle tissue mass decreases because of decreased size (atrophy)
and number (hypoplasia) of muscle fibers [4]. Mice exposed to adenine in our study
also suffer from muscle loss, depicted by decreased muscle weights in the CKD group.
Interestingly, when we studied EDL and Soleus muscle for fiber composition, we only
found reduced number of fibers and decreased diameter in the glycolytic EDL muscle.
Possible explanations for the decreased weight with conserved fiber number and size could
be an increased myofibrillar adipose tissue content or edema. Human studies have shown
that intramuscular triglyceride accumulation with insulin resistance is a common feature in
CKD and that the lipid deposition affects predominantly Type I fibers [31]. Therefore, it is
possible that the decrease in muscle weight with preserved number of fibers and diameter
in the Soleus muscle of our adenine-exposed mice is due to increased lipid deposition.
Prior studies in murine models have shown a muscle fiber switch from oxidative to
glycolytic fibers that could explain the lack of exercise endurance and early fatigability in
CKD mice [25,32]. Muscle fibers have been historically classified as fast-twitch fibers with
predominantly glycolytic metabolism or slow-twitch fibers with a preponderant oxidative
metabolism. Myosin ATPase staining correlates with speed of muscle shortening and has
led to classifying fibers as type II (fast twitching) or type I (slow twitching) fibers. Based
on fiber’s succinate dehydrogenase (SDH) staining to reflect oxidative metabolism, fibers
are subclassified as fatigue resistant (FR with increased SDH activity) or fast fatigable
(FF). Fibers can be classified using both ATPase and SDH staining as type IIa (FR or fast
oxidative-glycolytic) fibers or IIb (FF or fast glycolytic) fibers. Our study utilized monoclonal antibodies against myosin heavy chain (MyHC) isoforms to be able to differentiate
between fiber types and this facilitated the subclassification of type IIx fibers (with twitch
properties similar to IIa and IIb fibers and resistance to fatigue between IIa and IIb fibers).
Fiber typing characterization in murine and human studies have not shown congruent
results [25,32]. Specifically, Tamaki et al. showed a decrease in the proportion of type I (slow
oxidative) and IIa (fast oxidative glycolytic) and a relative increase in IIB (fast glycolytic)
muscle fibers in mice with CKD by SDH staining [25]. On the other hand, Higashihara
et al. demonstrated loss of fast type II fibers predominantly in his murine model of CKD by
myosin antibody staining in gastrocnemius muscle [32].
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These discrepancies are not only seen in murine studies but also in human studies.
In a recent cohort of fit subjects on maintenance dialysis awaiting kidney transplantation,
skeletal muscle studies demonstrated preserved muscle fiber cross-sectional area, and no
increase in sarcopenia, despite lower endurance capacity compared to controls. Fiber typing
studies of vastus lateralis muscle in the same cohort demonstrated a lower percentage of
MyHC type I fibers with higher percentage of other MyHC fibers, reflecting a switch from
slow to fast fiber type [33]. On the other hand, in a similar study by Lewis et al. [34], on
vastus lateralis muscle biopsies of subjects on maintenance dialysis, there was a small but
significant increase in type I fibers with a small decrease in IIx fibers. Although the results
of the two studies may seem contradictory, in terms of the frequency of type I fibers in
CKD, there were methodological differences. Lewis et al. also studied SDH activity within
individual fibers of vastus lateralis and demonstrated lower SDH activity in each fiber
subtype in dialysis patients, consistent with the concept of decreased oxidative capacity in
muscle of CKD patients independently of the fiber type.
Our results in mice differ slightly from data with other models and highlight the
complexity of these muscle-profiling studies. The most commonly murine models used
in the literature are 5/6 nephrectomy and adenine dietary supplementation which affect
GFR differently and may induce different degrees of muscle dysfunction. Furthermore, the
adenine model is associated with decreased oral intake due to the aversion to adenine in
mice despite the use of casein to mask adenine taste, which may result in more significant
muscle loss and dysfunction. Human muscle is not as compartmentalized as that in
mice, with a mix of both glycolytic and oxidative fibers in muscle groups without a clear
preponderant type in human muscle. MyHC staining reflects gross metabolic groups
but specific metabolic stains such as SDH for oxidative potential or α-Glycerophosphate
Dehydrogenase for glycolytic potential may be needed to better delineate metabolic capacity
within specific groups.
We studied the mitochondrial electron transport chain (ETC) supercomplexes in our
model of CKD as a surrogate for muscle OXPHOS capacity. Dysfunction of ETC complexes has been described in age-related loss of kidney function [35] and in AKI [36].
Gastrocnemius muscle of mice with CKD demonstrated decreased mitochondrial ETC
supercomplexes and cytochrome C compared to control mice corroborating our prior data
in C2C12 cells exposed to uremic serum [29]. Correct assembly of the complex subunits is
necessary for proper function and activity of ETC, which is critical for mitochondrial fitness.
Our data on expression of metabolic enzymes also support a preponderant glycolytic
metabolism with increased expression of GLUT1, LDHA and PCK2. In contrast, Thome
et al. [26] described intact protein content of ETC subunits but decreased activity of the
mitochondrial dehydrogenase enzymes pyruvate dehydrogenase and alpha ketoglutarate
dehydrogenase. Functionally, the authors propose that a defect in matrix dehydrogenase
activity is the main driver of decreased mitochondrial metabolic activity. Impaired mitochondrial complex formation despite conserved absolute complex protein values has
been described in muscle of diabetic patients [37], so it is possible that the same is true in
muscle of mice with CKD. To better delineate this discrepancy and since dehydrogenases
plays a key role in oxidation of glucose, we studied uremic muscle utilization of fatty
acids. Our in vitro data using a cell model of uremic muscle demonstrated that there is
impaired mitochondrial metabolism when glucose is used as the main energy substrate,
but intact oxygen consumption rates are demonstrated when fatty acids are utilized. We
also showed a preponderance of glycolytic metabolism and ROS production demonstrated
by the production of lactate and H2 O2 when muscle cells are exposed to uremic serum.
Reductions in muscle OXPHOS in the context of CKD has been demonstrated by different groups including by our lab [25,38]. We previously showed that there is decreased
TOMM20 expression and mitotracker activity in C2C12 cells exposed to uremic serum as
well as ESRD patients [29]. Thome et al. demonstrated decreased oxygen consumption rates
in isolated mitochondria from mice with CKD using several carbohydrates as substrates.
In contrast to our data, the authors also demonstrated a decrease in OXPHOS conductance
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using fatty acids [26]. These different results could be explained by the difference in the
in vitro models. Studies on isolated mitochondria have shown that mitochondrial changes
in structure and function secondary to different disease processes are parallel but augmented when compared to studies on intact mitochondria in permeabilized fibers [39,40].
Thus, it is possible that changes in FAO with uremia have been exacerbated as they were
studied in isolated mitochondria. Studies that have focused on the role of the different
metabolic pathways in uremic sarcopenia are lacking. Conversely, the contribution of FAO,
glycolysis and glucose-derived oxidative phosphorylation is better delineated in kidney
tubular epithelial cells in CKD. Proximal tubular cells have high baseline energy demands
and have high number of mitochondria. It is widely recognized that cells with high baseline
metabolic rates use FAO as their main metabolic pathway due to the higher efficiency of
fatty acid oxidation in comparison with oxidation of glucose. Kidney tubular epithelial cells
in CKD have defects in FAO [41,42] and increased glycolysis [43–45]. Since mitochondrial
FAO contributes a large proportion to the body’s energy needs in fasting and in situations
of metabolic stress, it is possible that uremic muscle, which has reduced dehydrogenase
activity including reduced PDH activity, will switch to FAO from glucose catabolism as a
critical source of energy support. Studies in permeabilized myofibers may help to better
delineate the contribution of different substrates to muscle energy production in CKD. ROS
contributes to increased catabolism, increases muscle atrophy and affects muscle contractility [46,47]. Patients with CKD have higher peripheral markers of oxidative stress [48,49]
and there is also increased ROS production in uremic muscle, as we demonstrated in this
study. The contribution of locally produced ROS versus systemic ROS in CKD patients to
the progression of uremic myopathy is an area that has not been extensively studied and
deserves further attention in future studies [15].
Our study has several limitations. The model of adenine-induced nephropathy leads
to significant weight loss due to the limited food intake as adenine is poorly tolerated.
Hence, this model of CKD has a component of cachexia that may not be widely represented
in the human disease. The young age of the mice commonly used for the CKD models
(8 to 15 weeks old) could influence muscle physiology as the muscle development is still
immature. The adenine model induces tubule-interstitial kidney disease. Other kidney
diseases, such as diabetic kidney disease, have intrinsic metabolic changes that can also
affect muscle metabolism and may have different effects on muscle performance since
diabetes mellitus, independently of CKD, can affect muscle function.
In summary, our model of tubulo-interstitial CKD has sarcopenia and decreased
energy endurance with increased oxidative stress and reduced glucose-derived OXPHOS,
but without gross fiber typing changes in oxidative and glycolytic muscle groups with
preserved FAO. Detailed studies of energy utilization with different substrates in muscle of
advanced CKD models and patients are needed in the future to focus on specific therapeutic
approaches with focus in supporting specific metabolic pathways.
4. Materials and Methods
Animal care and use. Male and female C57BL/6 mice 8 to 10 weeks old (Strain 000664)
were obtained from Jackson Laboratories and fed a standard diet (PicoLab® Rodent Diet 20,
5053) or 0.2% adenine-containing diet (Modified LabDiet® PicoLab® Rodent Diet 20, 5053,
with 0.2% adenine A8626; Sigma) ad libitum for 4 weeks. All animal procedures were in
compliance with protocols approved by the Institutional Animal Care and Use Committee
at Thomas Jefferson University. All methods were carried out in accordance with relevant
NIH guidelines and regulations.
4.1. Exercise Tolerance Test
The exercise tolerance test was assessed using a motorized Exer3/6 Treadmill system
with shock counter (Columbus Instruments). Mice were acclimated for 3 consecutive days
to the treadmill, 2 days before the test with an experimental run for 10 min at 0 incline.
The test was performed with 0 incline and started at 0 m/min to 5 m/min (20 s of speed
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transition) maintained for 12 min with progressive speed increases for a total running
time of 90 min. Briefly, speed increased from 2.5 m/min (1 min of transition for each
speed increase) until 10 m/min every 12 min. For the next phase, the treadmill speed was
increased 2.5 m/min every 10 min until it reached a speed of 20 m/min. For the final
phase, the speed was increased every 6 min until the treadmill reached a final speed of
25 m/min that was maintained for 4 min. Blood lactate levels were measured pre- and
post-experimental run using a Lactate Plus Meter (Nova Biomedical, Waltham, MA, USA).
4.2. Blood Urea Nitrogen (BUN)
Analyzed from murine blood obtained by intracardiac puncture using the QuantiChromTM
Urea Assay Kit (DIUR-100) as directed by the manufacturer.
4.3. Complete Blood Count (CBC)
Analyzed in 50 µL of murine whole blood in a GENESISTM Veterinary Hematology
System by the Translational Research/Pathology Core at the Sidney Kimmel Cancer Center.
4.4. Trichrome Stain and Quantification
Wild type kidneys from mice on adenine diet were fixed in formalin, paraffin-embedded
and four micron sections were cut and stained with Trichrome stain at the SKCC Translational Research/Pathology Shared Resource facility at Thomas Jefferson University. The
amount of fibrosis in each kidney sample (n = 6) was scored by two independent observers
at 20× magnification using the scale 1 = <25%, 2 = 25–50%, 3 = 50–75%, 4 = >75%. A total
of 21–25 cortical fields were scored and the average overall score was generated for each
kidney [50–53].
4.5. Collagen III Immunohistochemistry and Quantification
Four micron paraffin sections of mouse kidney were stained with goat antibody to
collagen III alpha 1/COL3A1 (Novus Biologicals #NBP1-26547) using a three-step avidinbiotin horseradish peroxidase method (Vector Labs, Newark, CA, USA). Briefly, sections
were deparaffinized, rehydrated and antigen retrieval was performed using 10 mM sodium
citrate, pH 6.0 buffer for 10 min using an electric pressure cooker. After cooling, sections
were blocked with 3% hydrogen peroxide and incubated overnight at 4 ◦ C with 10% normal
rabbit serum. Primary antibody was incubated for one hour at room temperature, followed
by blocking for endogenous biotin using the Biocare Medical Avidin Biotin kit (#AB972H).
Secondary and tertiary steps were for 30 min each and labeling for collagen 3 was detected
using the SignalStain DAB Substrate kit (Cell Signaling #8059). Kidney sections stained
for Collagen 3 were scanned using the Leica Aperio CS2 Scanscope at 20× and staining
quantification was performed using Aperio Imagescope. Specifically for quantification,
27–31 separate cortical regions from each section were analyzed using the Positive Pixel
Count v9 algorithm (5 animals per group), giving the ratio of total Collagen 3 positively
stained pixels to the total number (stained and unstained) pixels in each region.
4.6. Muscle Fiber Typing and Measurements
EDL and Soleus muscles were frozen in isopentane cooled with liquid nitrogen and
sectioned at eight microns. Fiber typing immunofluorescence was performed using MyHC
subtype specific antibodies, Type I (clone BA-D5), Type 2a (clone SC-71) and Type 2b (clone
BF-F3; Developmental Studies Hybridoma Bank, Iowa City, IA, USA). Briefly, sections were
washed in PBS, blocked with anti-mouse Fab fragments (#715-007-003, Jackson ImmunoReseach, West Grove, PA, USA) and incubated with anti-MyHC antibodies for one hour at
37 ◦ C. After washing in PBS, mouse IgG subtype-specific secondary antibodies (Jackson ImmunoResearch) were used for detection. Goat anti-mouse IgG2b Dylight 405 (#115-475-207)
for Type I fibers, goat anti-mouse IgG1 Alexa 488 (#115-545-205) for Type 2a fibers and goat
anti-mouse IgM Rhod Red X (#115-295-075) for Type 2b fibers. Rabbit anti-Laminin (#L9393,
Sigma-Aldrich, St. Louis, MO, USA) was used to stain the muscle fiber sarcolemma and
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detected with anti-rabbit Alexa 647 (#A21245, ThermoFisher, Eugene, OR, USA). Slides
were mounted with ProLong Gold (#P36934, ThermoFisher) and imaged with a Nikon
A1R confocal microscope at 10× using the tiling feature to create a composite of the entire
fiber. Muscle fibers stained for MyHC subtypes were measured using Fiji software. The
cell counter feature was used to enumerate the different fiber subtypes. Blue-stained fibers
are classified as Type 1, green fibers as Type 2A, red fibers as Type 2B and unstained fibers
as Type 2X. Laminin staining (Far Red) was imaged as purple or white to outline the
individual fiber membrane borders. Fiber sizes for each subtype were also measured and
the values generated for minimum Feret diameter were used to evaluate fiber sizes.
4.7. Human Serum Treatment
For the experiments with uremic serum exposure, uremic serum was collected, prior
to dialysis after the longest break (either on Monday or Tuesday), from a pool of stable
in-center hemodialysis (HD) subjects. In total, 10 mL of uremic serum were drawn from
~100 HD subjects in their usual state of health (subjects were excluded if they had Hepatitis
C, Hepatitis B or known or suspected acute infections). For the normal serum, 10 mL
of normal serum was drawn from 50 kidney donors in their usual state of health before
donation. Serum from HD subjects and kidney donors was pooled, filtered and aliquoted
in small vials and frozen at −80 ◦ C for cell experiments.
4.8. Cell Culture
C2C12 (CRL-1772, ATCC, Manassas, VA, USA) cells were used as a model of murine
myoblasts/myotubes and cultured according to the manufacturer’s recommendations.
Briefly, C2C12 cells were cultured in 10% fetal bovine serum (30-2020, ATCC) supplemented
DMEM (30-2002, ATCC). For myotube formation, when confluent, myoblasts underwent
differentiation by growth in DMEM containing 2.5% horse serum (16050130, Gibco) for
five days.
4.9. Oxygen Consumption Rates (OCR) Measurement
C2C12 cells were plated and differentiated on Seahorse XF 24-well plates (100777-004,
Agilent, Santa Clara, CA, USA). Cells were exposed to control or uremic serum for 24 h,
and incubated in Seahorse XF DMEM medium (103334-100, Agilent), supplemented with
5 mM glucose (103577-100, Agilent) at 37 ◦ C for 45 min without CO2 just before running
the experiments. Seahorse XF Cell Mito Stress Test Kit (103015-100, Agilent) was used
with the final respiratory modulators concentration of 1.5 µM for Oligomycin, 1 µM for
FCCP and 0.5 µM for Rotenone/Antimycin A. OCR measurements were obtained using
the Seahorse XFe24 Analyzer, and normalized to protein concentration (µg/µL). For the
FAO experiments the Seahorse XF Palmitate Oxidation Stress Test Kit (102720-100, Agilent)
was used following manufacturer’s recommendations. Similarly, cells were incubated for
24 h on substrate-limited medium supplemented with either control or uremic serum and
then changed to FAO assay medium to incubate at 37 ◦ C for 60 min. Prior to starting the
assay, Palmitate-BSA substrate or BSA control was added to the cells. OCR was analyzed
using Seahorse XFe96 Analyzer, and normalized to protein concentration (µg/µL).
4.10. Extracellular Lactate Measurement
C2C12 cells were exposed to serum in 12-well plates. After 24 h, cells were washed, and
media replaced by fresh DMEM supplemented with 10% FBS. The cell culture supernatants
were collected after 24 h and 48 h. Extracellular L-lactate concentration was measured
using the EnzyChrom L-lactate Assay Kit (ECLC-100, BioAssay Systems) according to the
manufacturer’s protocol. Results were normalized to total protein content (µg).
4.11. Extracellular H2 O2 Production
C2C12 cells were seeded in 12-well plates with 2 × 105 of cells per well and treated
with 5% normal or uremic serum for 24 h. Then, cells were washed and incubated with
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DMEM media and 2.5 µM of PFBSF (10005983; Cayman, Ann Arbor, CA, USA). After
45 min, cells were washed and sorted on an LSR II Flow Cytometer (BD Biosciences,
Franklin Lakes, NJ, USA). Data were analyzed using FlowJo 10.6 software.
4.12. Western Blot
Protein extraction, quantification and immunoblotting were performed as previously
described [29]. Briefly, frozen gastrocnemius muscle was pulverized with mortar and pestle
and homogenized in T-PER™ Tissue Protein Extraction Reagent (#78510, Thermofisher)
with cOmplete™, Mini Protease Inhibitor Cocktail (#11836153001, Roche) and Halt™ Protease and Phosphatase Inhibitor Cocktail (#78442, Thermofisher). Primary antibodies
used were anti-Glucose transporter 1 (#12939; Cell Signaling, Canvers, MA, USA), antiPhosphoenolpyruvate carboxykinase (#8565; Cell Signaling), anti-Lactate dehydrogenase
(#2012; Cell Signaling), anti-Monocarboxylate transporter 4 (sc-50329; SantaCruz), antiVinculin (#4650; Cell Signaling), anti-Translocase of the outer mitochondrial membrane
complex subunit 20 (sc-17764; SantaCruz, Santa Cruz, CA, USA), anti-Glyceraldehyde-3phosphate dehydrogenase (#2118; Cell Signaling), anti-Cytochrome c (#4280; Cell Signaling),
anti-β-actin (A5441; Sigma) and anti-OXPHOS cocktail (MS601; Abcam, Cambridge, UK).
4.13. Statistical Analysis
All results were expressed as mean and standard error of the mean for normalized data
or median and interquartile range for non-normalized data using GraphPad prism. Data
were analyzed using two-tailed t tests for comparisons between two groups for normalized
data and Mann–Whitney U test for non-normal data. A p value of <0.05 was considered
statistically significant.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/ijms232113515/s1, Figure S1: Renal histology of mice exposed to
0.2% adenine diet; Figure S2: Lactate production in C2C12 cells exposed to uremic serum.
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